Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

Table 1 Baseline characteristics and laboratory findings of patients who underwent RAV test

	Total (n = 142)	RAV negative (n = 113)	RAV positive (n = 29)	P value
Male, n (%)	53 (37.3%)	43 (38%)	10 (35%)	0.723
Age, years	58 ± 14	55 ± 14	66 ± 11	< 0.001
LC, n (%)	49 (34.5%)	36 (32%)	13 (45%)	0.190
Treatment experienced, n (%)	25 (17.6%)	19 (17%)	6 (21%)	0.624
AST, IU/L	58.4 ± 36.5	59.1 ± 38.9	56.0 ± 25.9	0.685
ALT, IU/L	51.5 ± 52.0	52.9 ± 55.5	46.0 ± 35.3	0.526
Total bilirubin, mg/dL	0.91 ± 0.52	0.92 ± 0.5	0.87 ± 0.34	0.601
HCV RNA, × 10⁶ IU/mL	2.241 ± 2.996	2.046 ± 3.024	3.013 ± 2.799	0.127

All results are presented as n (%) or mean ± SD
LC liver cirrhosis, AST aspartate aminotransferase, ALT alanine aminotransferase, RAV resistance-associated variant

ISSN: 1743-422X